West Paces Advisors Inc. Reduces Stock Holdings in Pfizer Inc. (NYSE:PFE)

West Paces Advisors Inc. decreased its position in Pfizer Inc. (NYSE:PFE) by 31.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,777 shares of the biopharmaceutical company’s stock after selling 2,213 shares during the period. West Paces Advisors Inc.’s holdings in Pfizer were worth $133,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of PFE. Kwmg LLC lifted its position in shares of Pfizer by 7.1% during the first quarter. Kwmg LLC now owns 134,132 shares of the biopharmaceutical company’s stock worth $3,722,000 after acquiring an additional 8,912 shares in the last quarter. Prentice Wealth Management LLC increased its position in shares of Pfizer by 11.8% during the first quarter. Prentice Wealth Management LLC now owns 13,152 shares of the biopharmaceutical company’s stock valued at $365,000 after acquiring an additional 1,390 shares in the last quarter. Thompson Investment Management Inc. increased its position in shares of Pfizer by 3.6% during the first quarter. Thompson Investment Management Inc. now owns 368,225 shares of the biopharmaceutical company’s stock valued at $10,218,000 after acquiring an additional 12,651 shares in the last quarter. Hoxton Planning & Management LLC increased its position in shares of Pfizer by 73.7% during the first quarter. Hoxton Planning & Management LLC now owns 16,728 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 7,097 shares in the last quarter. Finally, Sarasin & Partners LLP grew its position in Pfizer by 1.6% in the 1st quarter. Sarasin & Partners LLP now owns 1,405,135 shares of the biopharmaceutical company’s stock worth $38,992,000 after purchasing an additional 22,504 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 1.3 %

PFE stock traded down $0.38 during trading on Tuesday, reaching $27.99. 26,293,741 shares of the stock were exchanged, compared to its average volume of 41,148,078. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The business has a 50 day moving average price of $27.72 and a 200-day moving average price of $27.70. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $37.80. The firm has a market capitalization of $158.58 billion, a price-to-earnings ratio of -470.09, a P/E/G ratio of 1.09 and a beta of 0.70.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same period in the previous year, the firm earned $1.23 earnings per share. Pfizer’s quarterly revenue was down 19.5% compared to the same quarter last year. On average, research analysts predict that Pfizer Inc. will post 2.37 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Friday, May 10th were issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.00%. The ex-dividend date of this dividend was Thursday, May 9th. Pfizer’s payout ratio is -2,799.53%.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research analyst reports. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, June 17th. Finally, Morgan Stanley boosted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.